Incannex Healthcare INC 8-K filings

Incannex Healthcare has secured approximately A$6.9 million in funding through a facility agreement linked to its research and development expenses.

Incannex Healthcare announced its fiscal year 2024 financial results, highlighted by a strategic financing agreement, positive clinical trial results, and progress across multiple drug development programs.

Incannex Healthcare has secured up to $60 million in financing through a convertible note and equity line of credit agreement with Arena Investors and its affiliates.

Incannex Healthcare has entered into agreements for a $50 million equity line of credit and up to $10 million in convertible notes to bolster its financial position.

Incannex Healthcare has received FDA approval to begin a Phase 2 clinical trial for its psilocybin-assisted psychotherapy treatment for generalized anxiety disorder.

Incannex Healthcare has completed dosing in a 115-participant bioavailability/bioequivalence clinical trial for its sleep apnea drug candidate, IHL-42X, with no serious adverse events reported.

Incannex Healthcare has begun patient dosing in its Phase 2/3 clinical trial to assess the safety and efficacy of IHL-42X for obstructive sleep apnea.

Incannex Healthcare has successfully completed a pre-IND meeting with the FDA for its CannQuit-O treatment for opioid use disorder, marking a significant step forward in its development.

Incannex Healthcare announced its quarterly activities update, highlighting progress in clinical trials for sleep apnea, rheumatoid arthritis, and generalized anxiety disorder, as well as the opening of its first psychedelic-assisted therapy clinic.

Incannex Healthcare Inc. has appointed Joseph Swan as its new Chief Financial Officer and Secretary, effective February 29, 2024, following the resignation of Madhukar Bhalla.

Incannex Healthcare's Phase 2 trial of psilocybin-assisted therapy for generalized anxiety disorder demonstrated a statistically significant reduction in anxiety symptoms compared to placebo.

Incannex Healthcare has successfully completed a pre-IND meeting with the FDA for its CannQuit-N smoking cessation chewing gum, which combines CBD and nicotine.

Incannex Healthcare's Clarion Clinics in Melbourne has opened, with its Head of Psychiatry approved to prescribe MDMA and psilocybin for specific mental health conditions.

Incannex Healthcare has commenced dosing in a Phase 2 clinical trial for IHL-675A, a combination drug for rheumatoid arthritis.

Incannex Healthcare has completed dosing and treatment for all 72 participants in its Phase 2 PsiGAD clinical trial assessing psilocybin-assisted psychotherapy for generalized anxiety disorder, with topline results anticipated in the current quarter.

Incannex Healthcare has received Institutional Review Board (IRB) approval to begin its Phase 2/3 clinical trial for IHL-42X in patients with obstructive sleep apnea (OSA).